Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Post-ERCP Pancreatitis
Interventions: high dose indomethacin, standard dose indomethacin; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 1,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 6
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Immune Factors
Interventions: Olive Oil; Other
Lead sponsor: Tufts University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder, Neurogenic
Interventions: tamsulosin hydrochloride; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more

Conditions: Other Haemostasis Disorder, Haemorrhagic Cystitis
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Houston, Texas

Conditions: AML, MDS
Interventions: APVO436; Biological
Lead sponsor: Aptevo Research and Development LLC; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 12
States / cities: San Francisco, California • Denver, Colorado • Gainesville, Florida + 9 more

Conditions: Breast Cancer
Interventions: bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 1,613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 522
States / cities: Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more

Conditions: Hypertension
Interventions: GOALS, Minding GOALS; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 79 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: Dupilumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: High-Risk Percutaneous Coronary Intervention
Interventions: Impella ECP; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 32
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 27 more

Conditions: Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions: Copanlisib, Gemcitabine, Carboplatin, Dexamethasone, Rituximab, Pegfilgrastim; Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian Cancer
Interventions: flutamide; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 83 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Opioid Use Disorder
Interventions: Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg; Drug
Lead sponsor: Akyso Therapeutics, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Primary Health Care, Health Care Costs
Interventions: PACT Intensive Management; Behavioral
Lead sponsor: Veteran Affairs Office of Patient Care Services; Federal
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Basal Cell Carcinoma
Interventions: vismodegib (150 mg PO daily); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Postoperative Delirium, Pain, Postoperative, Degenerative Disc Disease
Interventions: Erector Spinae Block, Local infiltration with local anesthetic; Procedure
Lead sponsor: Rashmi Mueller; Other
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Graft Versus Host Disease (GVHD)
Interventions: Alpha-1 antitrypsin (AAT), Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 25
States / cities: Stanford, California • Gainesville, Florida • Tampa, Florida + 20 more

Conditions: Ovarian Cancer
Interventions: Olaparib tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Duarte, California • Newport Beach, California • Roseville, California + 10 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: miR Scientific LLC; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 2,019 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Stockbridge, Georgia • Farmingdale, New York

Conditions: Multiple Myeloma
Interventions: Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 234
States / cities: Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more

Conditions: Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions: Special Intervention; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 40 Years and older
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Post-operative Pulmonary Complications
Interventions: Heated humified high-flow nasal cannula Oxygen, Standard oxygen therapy; Device · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Leukemia, Lymphoma
Interventions: rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant; Biological · Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 69 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 25
States / cities: Duarte, California • Lewes, Delaware • Newark, Delaware + 18 more

Conditions: Acute Otitis Media
Interventions: amoxicillin/clavulanate postassium (Augmentin ES-600), azithromycin SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 48 Months
Enrollment: 902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Bellflower, California + 18 more

Search by objective public record fields.

Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis

Immunological Impact of High Olive Oil Consumption

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

Study of APVO436 in Patients With AML or MDS

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Minding GOALS: An Internet-Assisted Mind-Body-Behavior Program for Blood Pressure Control

Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

PIM 2.0: Patient Aligned Care Team (PACT) Intensive Management (PIM) Project

Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes

Erector Spinae Plane Block vs Local Infiltration Following Fusion Surgery

Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Sonographic Visibility of Breast Biopsy Marker Clips Up to 4 Weeks After Placement

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

Latinos Understanding the Need for Adherence

Impact of Prophylactic High Flow Nasal Oxygen in Post-Operative Thoracic Surgical Patients

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections